RNLX Renalytix AI ADS

RenalytixAI to Participate in the Stifel 2020 Healthcare Conference

RenalytixAI to Participate in the Stifel 2020 Healthcare Conference

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

RenalytixAI’s management is scheduled to present on Tuesday, November 17 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit .

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website (), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:

EN
13/11/2020

Underlying

RNLXRenalytix AI ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Renalytix AI ADS

 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Commencement of trading on OTCQB in the United States

Commencement of trading on OTCQB in the United States Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depo...

October 8, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collab...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno’), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chro...

July 11, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard t...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings p...

June 27, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Medicare Issues Final Coverage Determination for kidneyintelX.dkd Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's kidneyintelX.dkd testing. The final LCD can be accessed at , and is effective for dates of service on or after August 1, 2024. The established Medicare price for...

June 14, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage...

May 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch